Rejuvenation Technologies: Exploring Telomere Extension for Cellular Aging
What if some age-related diseases could be addressed by targeting a key mechanism of cellular aging?
That is the question Rejuvenation Technologies is exploring through therapeutic telomere extension.
A Propel(x) portfolio company, Rejuvenation Technologies is developing mRNA-based therapeutics. The company aims to temporarily activate telomerase in specific cells and extend shortened telomeres.
Telomeres protect the ends of chromosomes. They naturally shorten as cells divide. When they become critically short, they can contribute to cellular dysfunction and disease.
Rejuvenation Technologies is exploring whether restoring telomere length could help address diseases linked to this process.
Building a Platform for Telomere Extension
Rejuvenation Technologies continues to expand its technology platform and research.
The company reports:
- 40+ granted patents covering its technology
- More than $8 million in grant funding since 2023
- Research showing more than five years of telomere shortening reversed in one day in human cells
- Development programs focused on pulmonary fibrosis, liver disease, and bone marrow disorders
- A proprietary approach that combines telomerase mRNA with targeted lipid nanoparticles
These efforts bring together cellular biology, mRNA technology, and targeted drug delivery.
Using mRNA to Target Telomere Shortening
A key part of Rejuvenation Technologies’ approach is mRNA therapeutics.
The company uses mRNA to provide temporary instructions for producing telomerase. Telomerase can help extend shortened telomeres.
The approach does not aim to permanently change a cell’s genetic material. Instead, it seeks to create a temporary effect.
Rejuvenation Technologies is also developing targeted lipid nanoparticles. These nanoparticles aim to deliver the therapy to specific tissues.
This combination could provide a more targeted approach to therapeutic telomere extension.
Exploring Potential Treatments for Multiple Diseases
Rejuvenation Technologies is focusing on diseases linked to critically short telomeres.
Its development programs include pulmonary fibrosis, liver disease, and bone marrow disorders.
These conditions can involve cellular dysfunction and damage. The company is exploring whether telomere extension could help restore cellular function in affected tissues.
The research could also provide insights into how telomere biology contributes to human disease.
Advancing Toward Clinical Development
Rejuvenation Technologies raised $10.6 million in seed financing led by Khosla Ventures. The company also secured $4.6 million in grant funding.
The funding supports the advancement of its programs toward clinical development.
The company continues to develop its platform across telomere biology, mRNA therapeutics, and targeted delivery.
The Broader Opportunity in Cellular Aging
The work of Rejuvenation Technologies sits at the intersection of mRNA therapeutics, cellular biology, and regenerative medicine.
Telomere shortening is one of several biological processes linked to aging. Critically short telomeres can also contribute to specific diseases.
By targeting telomere shortening, Rejuvenation Technologies is exploring a potential new approach to cellular health.
The goal is not simply to extend lifespan. Instead, the company is investigating ways to address diseases linked to cellular aging.
We’re proud to see CEO John Ramunas and COO Glenn Markov, along with the Rejuvenation Technologies Inc. team, continue translating their research into potential therapeutic applications and advancing the science of cellular health.
Their work is helping advance research into telomere biology and cellular health.
Congratulations to the entire Rejuvenation Technologies team on its continued progress.
